Letters15 February 1998Light Microscopy of Indinavir Urinary CrystalsRaymonde F. Gagnon, MD, Christos M. Tsoukas, MD, and Andrew K. Watters, MDRaymonde F. Gagnon, MDMontreal General Hospital; Montreal, Quebec H3G 1A4, CanadaSearch for more papers by this author, Christos M. Tsoukas, MDMontreal General Hospital; Montreal, Quebec H3G 1A4, CanadaSearch for more papers by this author, and Andrew K. Watters, MDMontreal General Hospital; Montreal, Quebec H3G 1A4, CanadaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-4-199802150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the article by Kopp and colleagues [1]. The authors clearly show that indinavir, a protease inhibitor widely used in the treatment of HIV infection, forms distinctive urinary crystals.Indinavir is metabolized largely by the liver, but up to 10% of the compound is excreted intact in the urine [2]. The drug is generally well tolerated except for the formation of renal calculi, which has been reported with a frequency of 4% to 12% [3]. In a recent study [4], urinary calculi that were recovered from 29 patients with HIV infection consisted primarily of ...References1. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997; 127:119-25. Google Scholar2. Balani SK, Arison B, Mathai L, Kauffman LR, Miller RR, Stearns RA, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos. 1995; 23:266-70. Google Scholar3. Crixivan Product Monograph. Merck Frosst; 1996. Google Scholar4. Daudon M, Estepa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997; 349:1294-5. Google Scholar5. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy [Letter]. N Engl J Med. 1997; 336:138-40. Google Scholar Author, Article, and Disclosure InformationAuthors: Raymonde F. Gagnon, MD; Christos M. Tsoukas, MD; Andrew K. Watters, MDAffiliations: Montreal General Hospital; Montreal, Quebec H3G 1A4, Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and TreatmentDiagnostic examination of the child with urolithiasis or nephrocalcinosisIn-vitro crystallization of indinavir in the presence of ritonavir and as a function of pHAcute Renal FailureIndinavir Crystallization Around the Loop of Henle: Experimental EvidenceProspective study of urinalysis abnormalities in HIV-positive individuals treated with indinavirDetection of Indinavir Crystals in UrineIMAGING CHARACTERISTICS OF INDINAVIR CALCULIIMAGING CHARACTERISTICS OF INDINAVIR CALCULIPersistent Flank Pain, Low-Grade Fever, and Malaise in a Woman Treated with Indinavir 15 February 1998Volume 128, Issue 4Page: 321KeywordsEpidermal growth factorHIV infectionsKidney stonesLight microscopyLiverMicroscopyPatient advocacyProtease inhibitorsSulfatesUrine ePublished: 15 August 2000 Issue Published: 15 February 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Raymonde F. Gagnon (1998) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: